Últimas noticias sobre Sorrento Therapeutics (OTC:SRNE) Bolsa

Sorrento Therapeutics

Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

SORRENTO THERAPEUTICS INC by Sorrento Therapeutics, Inc.

Sorrento Therapeutics Inc

News

Dividends

Health Care

Press Releases

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

SCLX

SRNE

Cantor Fitzgerald

Comments

Sorrento Therapeutics

Noticias

Últimas noticias sobre Sorrento Therapeutics (OTC:SRNE) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL